These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3516291)

  • 1. Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenics.
    Syvälahti EK; Säkö E; Scheinin M; Pihlajamäki K; Hietala J
    Br J Psychiatry; 1986 Feb; 148():204-8. PubMed ID: 3516291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dopamine agonists in tardive dyskinesia.
    Smith RC; Tamminga CA; Haraszti J; Pandey GN; Davis JM
    Am J Psychiatry; 1977 Jul; 134(7):763-8. PubMed ID: 869053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxprenolol in schizophrenic patients with tardive dyskinesia: a double-blind placebo-controlled, crossover study.
    Karniol IG; Portela W
    Braz J Med Biol Res; 1982 Dec; 15(6):389-94. PubMed ID: 6135468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schizophrenic symptoms improve with apomorphine.
    Tamminga CA; Schaffer MH; Smith RC; Davis JM
    Science; 1978 May; 200(4341):567-8. PubMed ID: 347574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midification of tardive dyskinesia and spasmodic torticollis by apomorphine. Possible role of dopamine autoreceptors.
    Tolosa ES
    Arch Neurol; 1978 Jul; 35(7):459-62. PubMed ID: 666598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
    Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K
    Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effects of apomorphine in schizophrenia.
    Ferrier IN; Johnstone EC; Crow TJ
    Br J Psychiatry; 1984 Apr; 144():341-8. PubMed ID: 6372924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine.
    de Saint Victor JF; Pollak P; Gervason CL; Perret J
    Mov Disord; 1992; 7(3):283-4. PubMed ID: 1620148
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of apomorphine on schizophrenic symptoms.
    Smith RC; Tamminga C; Davis JM
    J Neural Transm; 1977; 40(2):171-6. PubMed ID: 323423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal effects of apomorphine in schizophrenia.
    Ferrier IN; Johnstone EC; Crow TJ
    Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia.
    Adelufosi AO; Abayomi O; Ojo TM
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010501. PubMed ID: 25866243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine.
    Tamminga CA; Gotts MD; Thaker GK; Alphs LD; Foster NL
    Arch Gen Psychiatry; 1986 Apr; 43(4):398-402. PubMed ID: 2869745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apomorphine response and subtyping of schizophrenia.
    Jeste DV; Zalcman S; Weinberger DR; Cutler NR; Bigelow LB; Kleinman JE; Rogol A; Wyatt RJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(1):83-8. PubMed ID: 6682989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
    Albani C; Zangger I; Fischer G
    Schweiz Rundsch Med Prax; 1992 Aug; 81(35):1011-5. PubMed ID: 1410978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
    Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
    J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tardive dystonia. The benefits of time.
    Cooper SJ; Doherty MM; King DJ
    Br J Psychiatry; 1989 Jul; 155():113-5. PubMed ID: 2691000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients.
    Branchey MH; Branchey LB; Richardson MA
    Am J Psychiatry; 1981 May; 138(5):608-12. PubMed ID: 7015884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study.
    Jus A; Villeneuve A; Gautier J; Jus K; Villeneuve C; Pires P; Villeneuve R
    Neuropsychobiology; 1978; 4(3):140-9. PubMed ID: 340975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.